Becker's Healthcare November 18, 2024
Alexandra Murphy

As President-elect Donald Trump prepares to take office, the future of Medicare’s drug price negotiation program, part of the 2022 Inflation Reduction Act, is uncertain, Roll Call reported Nov. 15.

The program, which allows the federal government to negotiate prices for high-cost drugs, is a key policy achievement of the Biden administration, but its future could be affected by changes under the new administration and Congress.

Here are four more things to know:

  1. Upon taking office, the Trump administration will be responsible for implementing the Medicare price negotiation program, which allows the government to negotiate prices on certain drugs starting in 2026. While Mr. Trump has previously supported Medicare price negotiations, his position on the current program...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
State Policy Levers Can Increase Enrollment In Medicare Savings Programs
ACP expresses support for proposed Medicare $2 Drug List Model
An Introduction to MIPS Basics
How Healthcare Leaders Reacted to the 15 Additional Drugs Selected for Medicare Negotiation Program
Lawmakers, experts weigh in on Medicare Drug Price Negotiation Program

Share This Article